Dilated Cardiomyopathy - Pipeline Review, H1 2019

Publisher Name :
Date: 31-Jan-2019
No. of pages: 70
Inquire Before Buying

Dilated Cardiomyopathy - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2019, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.

Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention and swelling (edema) in legs, ankles and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse and metabolic disorders, such as thyroid disease or diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Dilated Cardiomyopathy - Pipeline Review, H1 2019

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dilated Cardiomyopathy - Overview
Dilated Cardiomyopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Dilated Cardiomyopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dilated Cardiomyopathy - Companies Involved in Therapeutics Development
Array BioPharma Inc
Capricor Therapeutics Inc
Celixir Ltd
Hemostemix Inc
Martin Pharmaceuticals Inc
MyoKardia Inc
Dilated Cardiomyopathy - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARRY-797 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BC-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAP-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate BAG3 for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heartcel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LUS-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-440181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trimetazidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YS-1402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dilated Cardiomyopathy - Dormant Projects
Dilated Cardiomyopathy - Product Development Milestones
Featured News & Press Releases
Dec 11, 2018: MyoKardia reports positive data from phase 1b single-ascending dose clinical trial of MYK-491 in dilated cardiomyopathy and systolic heart failure patients
Dec 06, 2018: Berlin Cures steering committee is assembled to facilitate the design and implementation of phase 2 study of BC 007
Oct 30, 2018: MyoKardia Shares Data from new research program ACT-1 at 2018 R&D Day
Feb 26, 2018: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study
Feb 14, 2018: MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
Nov 02, 2017: MyoKardia Provides Update on MYK-491
Sep 27, 2017: MyoKardia Provides Update on MYK-491 Clinical Progress
Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
Dec 02, 2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491
Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Dilated Cardiomyopathy, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc, H1 2019
Dilated Cardiomyopathy - Pipeline by Capricor Therapeutics Inc, H1 2019
Dilated Cardiomyopathy - Pipeline by Celixir Ltd, H1 2019
Dilated Cardiomyopathy - Pipeline by Hemostemix Inc, H1 2019
Dilated Cardiomyopathy - Pipeline by Martin Pharmaceuticals Inc, H1 2019
Dilated Cardiomyopathy - Pipeline by MyoKardia Inc, H1 2019
Dilated Cardiomyopathy - Dormant Projects, H1 2019

List of Figures
Number of Products under Development for Dilated Cardiomyopathy, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
  • Global Digoxin Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 75
    According to our LPI (LP Information) latest study, the global Digoxin market size was valued at US$ 59 million in 2023. With growing demand in downstream market, the Digoxin is forecast to a readjusted size of US$ 73 million by 2030 with a CAGR of 3.2% during review period. The research report highlights the growth potential of the global Digoxin market. Digoxin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain op......
  • Global Heart Failure Drugs Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 116
    According to our LPI (LP Information) latest study, the global Heart Failure Drugs market size was valued at US$ million in 2023. With growing demand in downstream market, the Heart Failure Drugs is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Heart Failure Drugs market. Heart Failure Drugs are expected to show stable growth in the future market. However, product differentiatio......
  • Global Atorvastatin Calcium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 138
    According to our LPI (LP Information) latest study, the global Atorvastatin Calcium market size was valued at US$ 214.2 million in 2023. With growing demand in downstream market, the Atorvastatin Calcium is forecast to a readjusted size of US$ 362 million by 2030 with a CAGR of 7.8% during review period. The research report highlights the growth potential of the global Atorvastatin Calcium market. Atorvastatin Calcium are expected to show stable growth in the future market. However, prod......
  • Global Rosuvastatin Calcium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 139
    According to our LPI (LP Information) latest study, the global Rosuvastatin Calcium market size was valued at US$ 514.3 million in 2023. With growing demand in downstream market, the Rosuvastatin Calcium is forecast to a readjusted size of US$ 683.6 million by 2030 with a CAGR of 4.1% during review period. The research report highlights the growth potential of the global Rosuvastatin Calcium market. Rosuvastatin Calcium are expected to show stable growth in the future market. However, pr......
  • Global Atorvastatin Calcium Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 133
    According to our (Global Info Research) latest study, the global Atorvastatin Calcium market size was valued at USD 225.3 million in 2023 and is forecast to a readjusted size of USD 366.1 million by 2030 with a CAGR of 7.2% during review period. Atorvastatin calcium is a pharmaceutical raw material in the production of atorvastatin calcium drug (trade name: Lipitor), which is a prescription medicine that lowers the LDL cholesterol and triglycerides in the blood and can raise HDL choleste......
  • Global Rosuvastatin Calcium Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 132
    According to our (Global Info Research) latest study, the global Rosuvastatin Calcium market size was valued at USD 540.9 million in 2023 and is forecast to a readjusted size of USD 703.6 million by 2030 with a CAGR of 3.8% during review period. Rosuvastatin calcium (CAS 147098-20-2, molecular formula being C44H54CaF2N6O12S2) is the active pharmaceutical ingredient for the once-a-day dyslipidaemia treatment Crestor, it is one approved API which can be used to reduce the risk of heart att......
  • Cilostazol - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 118
    The global Cilostazol market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Cilostazol in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Cilostazol market. Injection Cilostazol, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Freeze-dried P......
  • Rosuvastatin - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 110
    Rosuvastatin medication is a statin that is used to lower bad cholesterol and prevent cardiovascular disease. It works by blocking an enzyme in the liver that makes cholesterol. It is taken by mouth and should be used together with dietary changes, exercise, and weight loss. It may also raise good cholesterol and lower triglycerides. It is sold under the brand name Crestor among others. It may be used when other statins have not worked well. The global Rosuvastatin market size is expected......
  • Global Congestive Heart Failure Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 19-Dec-2023        Price: US 3380 Onwards        Pages: 123
    Market Overview of Global Congestive Heart Failure Drugs market: According to our latest research, the global Congestive Heart Failure Drugs market looks promising in the next 5 years. As of 2022, the global Congestive Heart Failure Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Congestive heart failure is a serious and complex condition in which the heart muscles are either dam......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs